Sexually Transmitted Diseases (STDs) Treatment Market Trend 2021 | Industry Analysis, Global Size, Value Share, Sales Revenue and Top Key Players by Forecast to 2027
SEATTLE, April 09, 2021, (PHARMIWEB) — Global Sexually Transmitted Diseases (STDs) Treatment Market – Insights
Sexually transmitted disease (STD), also known as venereal disease, is an infection transmitted through sexual contact, caused by bacteria, viruses or parasites. Skin rashes, warts, abdominal pain or genital ulcers are some of the symptoms of STD. Enzyme Linked Immunosorbent Assay (ELISA), rapid plasma reagin blood test or antibody-absorption blood test is used for diagnosis of STDs.
To get holistic SAMPLE of the report including table of contents, please click https://www.coherentmarketinsights.com/insight/request-sample/2005
Global Sexually Transmitted Diseases (STDs) Treatment Market: Drivers
High prevalence of STDs is expected to boost growth of the global sexually transmitted diseases (STDs) treatment market. Among 20 STDs, the most common are Gonorrhea, Chlamydia, Syphilis, Herpes, Hepatitis (HBV), and Human Immunodeficiency Virus (HIV). For instance, according to the Centers for Disease Control and Prevention (CDC), 1,598,354 cases of Chlamydia trachomatis infection were reported in the U.S., corresponding to 497.3 cases per 100,000 in 2015. Furthermore, 468,514 gonorrhea cases were reported for a rate of 145.8 cases per 100,000 population, an increase of 18.5% from 2015. High prevalence of STDs can be attributed to unprotected sexual practices. For instance, according to World Health Organization (WHO), unsafe sex is ranked second among the top ten risk factors to health in terms of the burden of disease they cause.
Key players in the market are focused on product approval and launch to expand their product portfolio. For instance, in 2017, GSK and ViiV Healthcare applied to European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), for regulatory affiliation for a single-tablet, two-drug regimen of dolutegravir (by ViiV Healthcare) and rilpivirine (by Janssen) used for the treatment of HIV-1 infection. Some of the other drugs under development include, PrEP, PRO140 with ibalizumab, and BMS- 955176
Increasing initiatives by various governments regarding R&D for the treatment of STDs is also expected to contribute to growth of the market. For instance, British Columbia Center for Disease Control sponsored doxycycline (drug) studies for indication of syphilis and other sexually transmitted infection. The study was in early phase I clinical trial as of 2016. Several governments are also focused on increasing awareness regarding the treatment of STDs, which is expected to propel growth of the global sexually transmitted diseases (STDs) treatment market. For instance, in 2014, the CDC launched Improving Sexually Transmitted Disease Programs through Assessment, Assurance, Policy Development, and Prevention Strategies, or STD-AAPPS. Moreover, in 2018, Thunder Bay Group—HIV / AIDS / hepatitis C education and support services provider— expanded the access of hepatitis C medicine for individuals with level 2 hepatitis C, after negotiating with the provinces and drug manufacturers.
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2005
Global Sexually Transmitted Diseases (STDs) Treatment Market: Restraints
Low rate of screening for diseases and late diagnosis of the diseases such as HIV due to social stigma associated with STDs is expected to hinder growth of the global sexually transmitted diseases (STDs) treatment market.
Global Sexually Transmitted Diseases (STDs) Treatment Market – Regional Analysis
North America is expected to hold dominant position in the global sexually transmitted diseases (STDs) treatment market over the forecast period. This is attributed to increasing government support to spread awareness regarding treatment of STDs and introduction of prenatal screening programs in the region.
Asia Pacific is expected to witness the fastest growth in the global sexually transmitted diseases (STDs) treatment market over the forecast period. This is attributed to high prevalence of STDs in the region. For instance, according to Joint United Nations Program on HIV and AIDS (UNAIDS), Asia Pacific had the second-highest number of people living with HIV in the world i.e. 5.1 million as of 2016, Moreover, China, India, and Indonesia account for three quarters of the total people living with HIV in Asia Pacific.
Global Sexually Transmitted Diseases (STDs) Treatment Market – Competitive Landscape
Key players operating in the global sexually transmitted diseases (STDs) treatment market include, GlaxoSmithKline Plc, Merck & Co. Inc., Pfizer Inc., Gilead Sciences Inc., AbbVie Inc., Vertex Pharmaceuticals, Roche, Johnson & Johnson, and Bristol-Myers Squibb.
Key players in the market are focused on adopting collaboration strategies to expand their product portfolio. For instance, in 2017, the drug Zoloflodacin entered into clinical trials, as a result of partnership between Global Antibiotic Research and Development Partnership (GARDP) and Entasis Therapeutics. Moreover, in March 2018, Inovio Pharmaceuticals, Inc. entered into amended agreement providing ApolloBio Corp. exclusive rights for development, manufacturing, and commercialization of VGX – 3100, Inovio’s DNA immunotherapy product for pre-cancer indication.
Global Sexually Transmitted Diseases (STDs) Treatment Market – Taxonomy
By Disease Type
- Hepatitis (HBV)
- Human Immunodeficiency Virus (HIV)
- Other Indications
By Therapy Type
- Anti-bacterial drugs
- Anti-viral drugs
- Anti-fungal drugs
By Route of Administration
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire